Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis

Table 2 League table for adverse events

League table
Any grade AEs
HAIC	0.86 (0.47; 1.56)	0.88 (0.35; 2.22)		0.48 (0.25; 0.92)		0.16 (0.05; 0.54)
0.86 (0.47; 1.56)	HAIC + Lenv		0.76 (0.38; 1.55)
0.88 (0.35; 2.22)	1.03 (0.34; 3.09)	HAIC + A
0.66 (0.26; 1.66)	0.76 (0.38; 1.55)	0.74 (0.20; 2.75)	HAIC + Lenv + A
0.48 (0.25; 0.92)	0.56 (0.23; 1.35)	0.54 (0.18; 1.68)	0.73 (0.24; 2.27)	Sora	0.53 (0.22; 1.24)
0.25 (0.09; 0.74)	0.29 (0.09; 1.00)	0.29 (0.07; 1.18)	0.38 (0.09; 1.59)	0.53 (0.22; 1.24)	HAIC + Sora
0.16 (0.05; 0.54)	0.19 (0.05; 0.72)	0.19 (0.04; 0.84)	0.25 (0.06; 1.13)	0.34 (0.09; 1.33)	0.65 (0.13; 3.23)	TACE
3-4 grade AEs
HAIC + PD-1	0.26 (0.01; 6.54)
0.26 (0.01; 6.54)	HAIC	0.96 (0.22; 4.26)	0.63 (0.30; 1.31)		0.49 (0.09; 2.69)		0.32 (0.13; 0.75)
0.25 (0.01; 8.71)	0.96 (0.22; 4.26)	HAIC + Lenv		0.54 (0.05; 5.76)
0.16 (0.01; 4.45)	0.63 (0.30; 1.31)	0.65 (0.12; 3.43)	Sora					0.42 (0.14; 1.23)
0.13 (0.00; 9.57)	0.52 (0.03; 8.50)	0.54 (0.05; 5.76)	0.83 (0.05; 14.97)	HAIC + LENV + A
0.13 (0.00; 4.90)	0.49 (0.09; 2.69)	0.51 (0.05; 4.89)	0.79 (0.12; 5.02)	0.96 (0.04; 25.23)	HAIC + A
0.07 (0.00; 2.97)	0.29 (0.05; 1.70)	0.30 (0.03; 3.04)	0.46 (0.07; 3.16)	0.56 (0.02; 15.36)	0.58 (0.05; 6.78)	HAIC + TACE	1.10 (0.23; 5.19)
0.08 (0.00; 2.32)	0.32 (0.13; 0.75)	0.33 (0.06; 1.84)	0.51 (0.16; 1.59)	0.61 (0.03; 11.50)	0.64 (0.10; 4.30)	1.10 (0.23; 5.19)	TACE
0.07 (0.00; 2.21)	0.26 (0.07; 0.97)	0.27 (0.04; 1.97)	0.42 (0.14; 1.23)	0.51 (0.02; 11.17)	0.53 (0.06; 4.51)	0.91 (0.10; 8.28)	0.83 (0.17; 3.97)	HAIC + Sora
3-4 grade AEs for thrombocytopenia
Sora			0.27 (0.15; 0.46)		0.19 (0.01; 4.08)			0.11 (0.05; 0.24)
0.85 (0.02; 29.67)	HAIC + TACE + S-1	0.36 (0.01; 8.96)
0.30 (0.07; 1.37)	0.36 (0.01; 8.96)	HAIC + TACE				0.56 (0.20; 1.55)
0.27 (0.15; 0.46)	0.32 (0.01; 11.60)	0.89 (0.18; 4.42)	HAIC + Sora
0.24 (0.00; 14.92)	0.28 (0.00; 58.91)	0.78 (0.01; 56.14)	0.88 (0.01; 57.66)	HAIC + Lenv				0.47 (0.01; 27.94)
0.19 (0.01; 4.08)	0.22 (0.00; 24.56)	0.63 (0.02; 19.15)	0.70 (0.03; 15.97)	0.80 (0.00; 140.28)	HAIC + RT
0.17 (0.06; 0.52)	0.20 (0.01; 5.89)	0.56 (0.20; 1.55)	0.63 (0.18; 2.20)	0.72 (0.01; 46.14)	0.90 (0.03; 23.63)	TACE		0.66 (0.29; 1.47)
0.08 (0.00; 4.22)	0.09 (0.00; 17.21)	0.25 (0.00; 15.93)	0.29 (0.01; 16.31)	0.33 (0.00; 94.05)	0.41 (0.00; 63.25)	0.45 (0.01; 24.96)	HAIC + A	1.45 (0.03; 73.68)
0.11 (0.05; 0.24)	0.13 (0.00; 4.24)	0.37 (0.10; 1.35)	0.42 (0.16; 1.07)	0.47 (0.01; 27.94)	0.59 (0.02; 14.00)	0.66 (0.29; 1.47)	1.45 (0.03; 73.68)	HAIC	0.54 (0.03; 8.82)
0.06 (0.00; 1.09)	0.07 (0.00; 6.15)	0.20 (0.01; 4.33)	0.23 (0.01; 4.28)	0.26 (0.00; 35.95)	0.32 (0.00; 21.78)	0.36 (0.02; 6.48)	0.79 (0.01; 97.36)	0.54 (0.03; 8.82)	HAIC + PD-1
3-4 grade AEs for elevated total bilirubin
HAIC + Lenv			0.57 (0.01; 29.09)	0.34 (0.03; 4.22)
0.65 (0.02; 23.55)	HAIC + RT					0.49 (0.04; 5.61)
0.56 (0.01; 33.37)	0.86 (0.01; 51.75)	HAIC + PD-1		0.60 (0.02; 14.98)
0.57 (0.01; 29.09)	0.87 (0.00; 178.10)	1.01 (0.00; 293.95)	HAIC + LENV + A
0.34 (0.03; 4.22)	0.52 (0.04; 6.61)	0.60 (0.02; 14.98)	0.60 (0.01; 63.73)	HAIC		0.94 (0.46; 1.89)		0.23 (0.01; 5.65)	0.24 (0.09; 0.65)
0.32 (0.02; 4.68)	0.49 (0.04; 6.06)	0.57 (0.02; 16.06)	0.56 (0.00; 65.61)	0.94 (0.37; 2.38)	HAIC + Sora	1.00 (0.54; 1.84)
0.32 (0.02; 4.36)	0.49 (0.04; 5.61)	0.57 (0.02; 15.15)	0.56 (0.00; 62.97)	0.94 (0.46; 1.89)	1.00 (0.54; 1.84)	Sora
0.16 (0.01; 2.86)	0.25 (0.01; 4.46)	0.29 (0.01; 9.46)	0.28 (0.00; 36.96)	0.47 (0.12; 1.90)	0.51 (0.10; 2.68)	0.51 (0.11; 2.39)	HAIC + TACE		0.50 (0.19; 1.30)
0.08 (0.00; 4.58)	0.12 (0.00; 7.10)	0.14 (0.00; 12.89)	0.14 (0.00; 39.31)	0.23 (0.01; 5.65)	0.24 (0.01; 6.87)	0.24 (0.01; 6.50)	0.48 (0.01; 15.85)	HAIC + A
0.08 (0.01; 1.22)	0.12 (0.01; 1.90)	0.14 (0.00; 4.16)	0.14 (0.00; 16.88)	0.24 (0.09; 0.65)	0.25 (0.06; 1.00)	0.25 (0.07; 0.87)	0.50 (0.19; 1.30)	1.05 (0.04; 30.26)	TACE

AEs: Adverse events; HAIC: Hepatic arterial infusion chemotherapy; Sora: Sorafenib; Lenv: Lenvatinib; TACE: Transarterial chemoembolization; RT: Radiotherapy; S-1: A composite preparation of a 5-fluorouracil prodrug. A: Ablation; PD-1: Programmed death 1; BSC: Best supportive care; PR: Partial response; CR: Complete response; DCR: Disease control rate; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival.